u-PA expression in benign, borderline and malignant ovarian tumors

被引:0
|
作者
Kiziridou, AD
Toliou, T
Stefanou, D
Agnantis, N
机构
[1] Theagen Anticanc Inst thessaloniki, Dept Pathol, Thessaloniki 54007, Greece
[2] Univ Ioannina, Sch Med, Dept Pathol, Ioannina 45100, Greece
关键词
plasminogen activator; ovarian carcinoma; borderline tumors; immunohistochemistry;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The malignant potential of solid tumors is related to their ability to invade adjacent tissue and to metastasize. The plasminogen activation system is one of the critical factors in tumor progression since it is involved in tumor invasion and metastasis. This study was performed to examine the expression of u-PA in benign, borderline and malignant tumors of the ovary by immunohistochemical evaluation on formalin-fixed, paraffin-embedded specimens applying monoclonal antibody 3689 directed to the b-chain of u-PA. Normal epithelial cells of the ovary (n =5) showed no staining of u-PA but some stromal cells were slightly stained. Invasive carcinomas (n=16) and borderline tumors (n = 15) showed a moderate to strong diffuse cytoplasmic staining. Benign tumors (n=20) showed a variety of staining. The observation of randomly positive u-PA stromal cells is noteworthy. The percentage of u-PA-positive tumors was higher in carcinomas than in other tumors. There was no con-elation with other known risk factors of malignancy such as differentiation, stage or type of tumor, In conclusion there are noticeable differences in u-PA expression among ovarian tumors and u-PA increase in ovarian tumors can be attributed to an increased diffuse cytoplasmic content in the neoplastic epithelial cells.
引用
收藏
页码:985 / 990
页数:6
相关论文
共 50 条
  • [1] BORDERLINE OVARIAN TUMORS - ARE THEY BENIGN OR MALIGNANT?
    Lazarou, Anastasia
    Fotopoulou, Christina
    Coumbos, Alexandra
    Sehouli, Jalid
    Vasiljeva, Jekaterina
    Braicu, Ioana
    Burger, Heinz
    Kuehn, Wolfgang
    [J]. ANTICANCER RESEARCH, 2014, 34 (10) : 6257 - 6257
  • [2] Expression of human telomerase subunits in ovarian malignant borderline and benign tumors
    Kyo, S
    Kanaya, T
    Takakura, M
    Tanaka, M
    Yamashita, A
    Inoue, H
    Inoue, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1999, 80 (06) : 804 - 809
  • [3] Phenotypic analysis of ovarian carcinoma: Polypeptide expression in benign, borderline and malignant tumors
    Alaiya, AA
    Franzen, B
    Fujioka, K
    Moberger, B
    Schedvins, K
    Silversvard, C
    Linder, S
    Auer, G
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1997, 73 (05) : 678 - 683
  • [4] Comparison of benign, borderline, and malignant mucinous ovarian tumors
    Yamamoto, Y.
    Kunimi, Y.
    Wakikawa, A.
    Ueno, A.
    Nagai, R.
    Komatsu, J.
    Minami, S.
    Hayashi, K.
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 751 - 754
  • [5] Methylation profile in benign, borderline and malignant ovarian tumors
    K. F. Tam
    V. W. S. Liu
    S. S. Liu
    P. C. K. Tsang
    A. N. Y. Cheung
    A. M. W. Yip
    H. Y. S. Ngan
    [J]. Journal of Cancer Research and Clinical Oncology, 2007, 133 : 331 - 341
  • [6] Methylation profile in benign, borderline and malignant ovarian tumors
    Tam, K. F.
    Liu, V. W. S.
    Liu, S. S.
    Tsang, P. C. K.
    Cheung, A. N. Y.
    Yip, A. M. W.
    Ngan, H. Y. S.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2007, 133 (05) : 331 - 341
  • [7] Differential Nuclear Expression of Aurora A Kinase in Benign, Borderline, and Malignant Serous Ovarian Tumors
    Cratte, J. E.
    Sehultz, D. S.
    Inamdar, K. V.
    Lehman, N. L.
    [J]. MODERN PATHOLOGY, 2010, 23 : 238A - 238A
  • [8] p14 expression differences in ovarian benign, borderline and malignant epithelial tumors
    Vinicius Duarte Cabral
    Marcelle Reesink Cerski
    Ivana Trindade Sa Brito
    Lucia Maria Kliemann
    [J]. Journal of Ovarian Research, 9
  • [9] Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors
    Zagorianakou, N
    Stefanou, D
    Makrydimas, G
    Zagorianakou, P
    Briasoulis, E
    Karavasilis, V
    Pavlidis, N
    Agnantis, NJ
    [J]. HISTOLOGY AND HISTOPATHOLOGY, 2006, 21 (4-6) : 341 - 347
  • [10] Differential Nuclear Expression of Aurora A Kinase in Benign, Borderline, and Malignant Serous Ovarian Tumors
    Crane, J. E.
    Schultz, D. S.
    Inamdar, K. V.
    Lehman, N. L.
    [J]. LABORATORY INVESTIGATION, 2010, 90 : 238A - 238A